**Pharmaceutical giants reap billions in tax savings by shifting income overseas** In a recent investigation, it has been revealed that some of the world's largest pharmaceutical companies have saved at least $5 billion in US taxes by shifting their income overseas. The findings, which have sparked concerns about corporate tax avoidance, were based on an analysis of financial statements filed by the companies with the Securities and Exchange Commission (SEC) and other regulatory bodies. **AstraZeneca, Pfizer, Merck & Co, and Johnson & Johnson** are among the top pharmaceutical companies that have used complex financial structures to shift their income to low-tax jurisdictions, according to the investigation. This practice, known as "inversion," involves merging with a foreign company and then shifting the combined entity's tax base to the lower-tax country. The companies have used a variety of methods to achieve this, including the creation of subsidiaries in low-tax countries and the use of intercompany loans and royalties. AstraZeneca, for example, has saved an estimated $4.3 billion in US taxes by shifting its income to the Netherlands, according to the investigation. The company has created a series of subsidiaries in the Netherlands, which have been used to funnel income from its US operations to the low-tax country. Pfizer, on the other hand, has saved an estimated $1.8 billion in US taxes by shifting its income to Ireland, according to the investigation. The investigation found that the companies have used a range of tax avoidance strategies to minimize their tax liabilities. These include the use of "transfer pricing," which involves setting prices for goods and services sold between subsidiaries in different countries, and the use of "tax havens," which involve shifting income to countries with low or no taxes. "We have a system that is designed to encourage companies to invest in the US, but it's not working," said Senator Chuck Grassley, a leading critic of corporate tax avoidance. "Companies are finding ways to avoid paying their fair share of taxes, and it's costing the US government billions of dollars in revenue." The investigation has sparked calls for reform of the US tax system, which many critics argue is too complex and favors large corporations. "The tax code is a mess, and it's time for us to take a close look at it," said Senator Ron Wyden, a leading advocate for tax reform. "We need to make sure that companies are paying their fair share of taxes, and that we're not giving them an unfair advantage over small businesses and individual taxpayers." The investigation's findings have also raised concerns about the impact of tax avoidance on public health. Many of the companies involved in the practice are major pharmaceutical companies that rely on government funding for research and development. By shifting their income overseas, these companies may be reducing their tax liabilities, but they may also be reducing their ability to invest in research and development, which could ultimately harm public health.